VBI-2601

Further secures Brii’s rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company’s strategy for HBV functional cure DURHAM, NC, USA and BEIJING, China I December 31, 2024 I Brii Biosciences Limited (“Brii Bio,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs announced today that it has entered into an agreement with VBI Vaccines, Inc. and certain of its subsidiaries (“VBI”) and its creditor K2 VBI Equity Trust, LLC and K2 HealthVentures LLC, acquiring the intellectual property(IP) and other assets relating to BRII-179. Under the agreement, among other matters, the Company will fully acquire the BRII-179 patents, BRII-179 know-how, and relevant BRII-179 materials, eliminating all future milestones and royalty obligations payable to VBI. The total consideration to be paid by Brii is US$18 million. Upon the closing of this transaction, Brii and VBI will also terminate their agreements announced on February 14, 2024, which were not consummated due to the discontinuation of operations of VBI. All payment obligations of Brii under the terminated agreements other than the outstanding principal amount of US$2.5 million in the form of a promissory note will be cancelled. “This transaction ensures us with uninterrupted clinical supply of BRII-179 and complete ownership of its IP” said Dr. Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio. “It vests more value of BRII-179 in Brii’s shareholders as we advance to late-stage development.” Currently Brii has started several BRII-179-containing combination studies to pursue its strategy of achieving a higher functional cure rate for the patients with chronic Hepatitis B Virus (HBV) infection. Ongoing studies continue to support that BRII-179 has the potential to identify HBV patients more responsive to curative treatments. Based on the cumulative and emerging data, a large, prospective and confirmatory Phase 2b study evaluating sequential treatment of BRII-179 followed by elebsiran and PEG-IFNα combination (the ENRICH study) is now fully enrolled. About Hepatitis B Hepatitis B virus (HBV) infection is one of the world’s most significant infectious disease threats with more than 254 million people infected globally. [1] Chronic HBV infection is the leading cause of liver diseases and an estimated 820,000 people die of complications from chronic HBV infection each year. [1] HBV is of exceptional concern in China, where 87 million people are chronically infected. [2] About BRII-179 BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. Brii Bio licensed BRII-179 from VBI Vaccines, Inc. (“VBI”) in December 2018 and has extended the exclusive license to global rights since July 2023. In November 2023, the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration (the “NMPA”) granted BRII-179 Breakthrough Therapy Designation. About Brii Bio Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com . [1] World Health Organization. (April 2024). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from https://www-who-int.libproxy1.nus.edu.sg/publications/i/item/9789240091672 [2] World Health Organization. Hepatitis. World Health Organization. Retrieved from https://www-who-int.libproxy1.nus.edu.sg/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C SOURCE: Brii Biosciences

Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for HBV functional cure DURHAM, N.C. and BEIJING, Dec. 31, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs announced today that it has entered into an agreement with VBI Vaccines, Inc. and certain of its subsidiaries ("VBI") and its creditor K2 VBI Equity Trust, LLC and K2 HealthVentures LLC, acquiring the intellectual property(IP) and other assets relating to BRII-179. Under the agreement, among other matters, the Company will fully acquire the BRII-179 patents, BRII-179 know-how, and relevant BRII-179 materials, eliminating all future milestones and royalty obligations payable to VBI. The total consideration to be paid by Brii is US$18 million. Upon the closing of this transaction, Brii and VBI will also terminate their agreements announced on February 14, 2024, which were not consummated due to the discontinuation of operations of VBI. All payment obligations of Brii under the terminated agreements other than the outstanding principal amount of US$2.5 million in the form of a promissory note will be cancelled. "This transaction ensures us with uninterrupted clinical supply of BRII-179 and complete ownership of its IP" said Dr. Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio. "It vests more value of BRII-179 in Brii's shareholders as we advance to late-stage development." Currently Brii has started several BRII-179-containing combination studies to pursue its strategy of achieving a higher functional cure rate for the patients with chronic Hepatitis B Virus (HBV) infection. Ongoing studies continue to support that BRII-179 has the potential to identify HBV patients more responsive to curative treatments. Based on the cumulative and emerging data, a large, prospective and confirmatory Phase 2b study evaluating sequential treatment of BRII-179 followed by elebsiran and PEG-IFNα combination (the ENRICH study) is now fully enrolled. About Hepatitis B Hepatitis B virus (HBV) infection is one of the world's most significant infectious disease threats with more than 254 million people infected globally.[1] Chronic HBV infection is the leading cause of liver diseases and an estimated 820,000 people die of complications from chronic HBV infection each year.[1] HBV is of exceptional concern in China, where 87 million people are chronically infected.[2] About BRII-179 BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. Brii Bio licensed BRII-179 from VBI Vaccines, Inc. ("VBI") in December 2018 and has extended the exclusive license to global rights since July 2023. In November 2023, the Center for Drug Evaluation (the "CDE") of the National Medical Products Administration (the "NMPA") granted BRII-179 Breakthrough Therapy Designation. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit . [1] World Health Organization. (April 2024). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from [2] World Health Organization. Hepatitis. World Health Organization. Retrieved from SOURCE Brii Biosciences Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED